Research programme: HIV/AIDS therapeutic lentivirus - American Gene Technologies

Drug Profile

Research programme: HIV/AIDS therapeutic lentivirus - American Gene Technologies

Alternative Names: AG 1105; AG1105 - AIDS therapeutics lentivirus

Latest Information Update: 01 Aug 2016

Price : $50

At a glance

  • Originator American Gene Technologies International
  • Developer American Gene Technologies International; University of Maryland, Baltimore
  • Class Gene therapies
  • Mechanism of Action Gene transference; HIV replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 01 Aug 2016 Preclinical trials in HIV infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top